← Back to home

HER2 EXPRESSION GASTRIC CANCER/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Clinical trials for HER2 EXPRESSION GASTRIC CANCER/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new HER2 EXPRESSION GASTRIC CANCER/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear

Sign up with your email to follow new studies for HER2 EXPRESSION GASTRIC CANCER/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug combo trial offers hope for tough stomach cancers

Disease control Recruiting now

This study is testing a new drug called SHR-A1811, given with chemotherapy and/or immunotherapy, for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The first part checks the safety and best dose of the combinations. The second part measures how we…

Matched conditions: HER2 EXPRESSION GASTRIC CANCER/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Phase: PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control

Last updated Mar 31, 2026 12:11 UTC

HER2 EXPRESSION GASTRIC CANCER/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Get alerted when new HER2 EXPRESSION GASTRIC CANCER/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear

New drug combo trial offers hope for tough stomach cancers